RU2502721C2 - Способ получения производных 1-(2-галогенобифенил-4-ил)-циклопропанкарбоновой кислоты - Google Patents
Способ получения производных 1-(2-галогенобифенил-4-ил)-циклопропанкарбоновой кислоты Download PDFInfo
- Publication number
- RU2502721C2 RU2502721C2 RU2010146299/04A RU2010146299A RU2502721C2 RU 2502721 C2 RU2502721 C2 RU 2502721C2 RU 2010146299/04 A RU2010146299/04 A RU 2010146299/04A RU 2010146299 A RU2010146299 A RU 2010146299A RU 2502721 C2 RU2502721 C2 RU 2502721C2
- Authority
- RU
- Russia
- Prior art keywords
- formula
- compound
- fluoro
- biphenyl
- dichloro
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 229910052736 halogen Inorganic materials 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 74
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 28
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000031709 bromination Effects 0.000 claims abstract description 10
- 238000005893 bromination reaction Methods 0.000 claims abstract description 10
- 229910052763 palladium Inorganic materials 0.000 claims abstract description 10
- 239000003054 catalyst Substances 0.000 claims abstract description 8
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 8
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004342 Benzoyl peroxide Substances 0.000 claims abstract description 5
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims abstract description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019400 benzoyl peroxide Nutrition 0.000 claims abstract description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 5
- 230000003197 catalytic effect Effects 0.000 claims abstract description 5
- 239000000460 chlorine Substances 0.000 claims abstract description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 5
- 230000007062 hydrolysis Effects 0.000 claims abstract description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 5
- 150000002825 nitriles Chemical class 0.000 claims abstract description 4
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- VXARNRWZIXSZQV-UHFFFAOYSA-N 1,2-dichloro-4-(2-fluoro-4-methylphenyl)benzene Chemical group FC1=CC(C)=CC=C1C1=CC=C(Cl)C(Cl)=C1 VXARNRWZIXSZQV-UHFFFAOYSA-N 0.000 claims description 6
- VIAGWCCTVXKMIP-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carbonitrile Chemical compound FC1=CC(C2(CC2)C#N)=CC=C1C1=CC=C(Cl)C(Cl)=C1 VIAGWCCTVXKMIP-UHFFFAOYSA-N 0.000 claims description 6
- CWCQHXOAFSQEDX-UHFFFAOYSA-N 2-[4-(3,4-dichlorophenyl)-3-fluorophenyl]acetonitrile Chemical group FC1=CC(CC#N)=CC=C1C1=CC=C(Cl)C(Cl)=C1 CWCQHXOAFSQEDX-UHFFFAOYSA-N 0.000 claims description 6
- BLTDKTSROKGAOD-UHFFFAOYSA-N 4-(bromomethyl)-1-(3,4-dichlorophenyl)-2-fluorobenzene Chemical group FC1=CC(CBr)=CC=C1C1=CC=C(Cl)C(Cl)=C1 BLTDKTSROKGAOD-UHFFFAOYSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- LIYLTQQDABRNRX-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenyl)-3-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound C=1C=C(C=2C=C(Cl)C(Cl)=CC=2)C(F)=CC=1C1(C(=O)O)CC1 LIYLTQQDABRNRX-UHFFFAOYSA-N 0.000 claims description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- JKIGHOARKAIPJI-UHFFFAOYSA-N (3,4-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C(Cl)=C1 JKIGHOARKAIPJI-UHFFFAOYSA-N 0.000 claims description 3
- SLFNGVGRINFJLK-UHFFFAOYSA-N 1-bromo-2-fluoro-4-methylbenzene Chemical compound CC1=CC=C(Br)C(F)=C1 SLFNGVGRINFJLK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 238000011097 chromatography purification Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000010992 reflux Methods 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- -1 methylenedioxy Chemical group 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001843 polymethylhydrosiloxane Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 0 *c1cc(CC#N)ccc1-c1ccccc1 Chemical compound *c1cc(CC#N)ccc1-c1ccccc1 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- LBFCLYWVFCDUNL-UHNVWZDZSA-N C[C@H](C[C@H](C)I)F Chemical compound C[C@H](C[C@H](C)I)F LBFCLYWVFCDUNL-UHNVWZDZSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000005888 cyclopropanation reaction Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
- C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
- C07C17/14—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms in the side-chain of aromatic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/14—Preparation of carboxylic acid nitriles by reaction of cyanides with halogen-containing compounds with replacement of halogen atoms by cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08158022A EP2133322A1 (en) | 2008-06-11 | 2008-06-11 | Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid |
| EP08158022.7 | 2008-06-11 | ||
| PCT/EP2009/003288 WO2009149797A1 (en) | 2008-06-11 | 2009-05-08 | Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010146299A RU2010146299A (ru) | 2012-07-20 |
| RU2502721C2 true RU2502721C2 (ru) | 2013-12-27 |
Family
ID=40120119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010146299/04A RU2502721C2 (ru) | 2008-06-11 | 2009-05-08 | Способ получения производных 1-(2-галогенобифенил-4-ил)-циклопропанкарбоновой кислоты |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8076505B2 (enExample) |
| EP (2) | EP2133322A1 (enExample) |
| JP (1) | JP5642067B2 (enExample) |
| KR (1) | KR101257217B1 (enExample) |
| CN (1) | CN102046576B (enExample) |
| AT (1) | ATE552230T1 (enExample) |
| AU (1) | AU2009256959B2 (enExample) |
| BR (1) | BRPI0909560A2 (enExample) |
| CA (1) | CA2723878C (enExample) |
| CO (1) | CO6331461A2 (enExample) |
| DK (1) | DK2285765T3 (enExample) |
| ES (1) | ES2384368T3 (enExample) |
| GE (1) | GEP20135800B (enExample) |
| HR (1) | HRP20120517T1 (enExample) |
| IL (1) | IL209209A (enExample) |
| MA (1) | MA32297B1 (enExample) |
| ME (1) | ME01160B (enExample) |
| MX (1) | MX2010012285A (enExample) |
| MY (1) | MY150280A (enExample) |
| NZ (1) | NZ589087A (enExample) |
| PL (1) | PL2285765T3 (enExample) |
| PT (1) | PT2285765E (enExample) |
| RU (1) | RU2502721C2 (enExample) |
| SI (1) | SI2285765T1 (enExample) |
| UA (1) | UA101835C2 (enExample) |
| WO (1) | WO2009149797A1 (enExample) |
| ZA (1) | ZA201007977B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE409176T1 (de) * | 2003-02-21 | 2008-10-15 | Chiesi Farma Spa | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen |
| CN102596879B (zh) * | 2009-08-04 | 2015-01-28 | 奇斯药制品公司 | 制备1-(2-卤代联苯-4-基)-环丙烷羧酸的衍生物的方法 |
| KR20130036210A (ko) * | 2010-04-01 | 2013-04-11 | 키에시 파르마슈티시 엣스. 피. 에이. | 신규 다형체 및 염 |
| ES2526522T3 (es) * | 2010-04-21 | 2015-01-13 | Chiesi Farmaceutici S.P.A. | Derivados del ácido 1-(2-fluorobifenil-4-il)alquil carboxílico para la terapia de la amiloidosis transtiretina |
| CN102905701A (zh) | 2010-06-04 | 2013-01-30 | 奇斯药制品公司 | 用于治疗朊病毒病的1-(2-氟联苯-4-基)-环丙烷羧酸衍生物 |
| US9592210B2 (en) | 2011-12-22 | 2017-03-14 | Chiesi Farmaceutici S.P.A. | 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment |
| EP2834214A1 (en) | 2012-04-04 | 2015-02-11 | Chiesi Farmaceutici S.p.A. | Derivatives of 1-(2-halo-biphenyl-4-yl)- alkanecarboxylic acids for the treatment of neurodegenerative diseases |
| EP2818460A1 (en) | 2013-06-24 | 2014-12-31 | ZaCh System S.p.A. | Cyclopropanation of substituted phenylacetonitriles or phenyl acetates |
| CA2915773A1 (en) | 2013-06-24 | 2014-12-31 | Chiesi Farmaceutici S.P.A. | Improved process for the preparation of derivatives of 1-(2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid |
| WO2015181094A1 (en) | 2014-05-26 | 2015-12-03 | Chiesi Farmaceutici S.P.A. | 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the treatment of down's syndrome |
| CN107698462A (zh) * | 2017-10-10 | 2018-02-16 | 重庆科脉生物化工有限公司 | 一种1‑氨基‑1‑环丙腈盐酸盐的制备方法 |
| AU2022338032A1 (en) | 2021-08-31 | 2024-03-07 | Cerespir Incorporated | Co-crystals |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004074232A1 (en) * | 2003-02-21 | 2004-09-02 | Chiesi Farmaceutici S.P.A. | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases |
| WO2006133559A1 (en) * | 2005-06-14 | 2006-12-21 | Merck Frosst Canada Ltd. | Reversible inhibitors of monoamine oxidase a and b |
| EA200700860A1 (ru) * | 2004-10-21 | 2007-10-26 | Целльцом Аг | (бифенил)карбоновые кислоты и их производные |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4507294B2 (ja) * | 1999-05-27 | 2010-07-21 | チッソ株式会社 | ビアリール誘導体の製造方法 |
| JP4502293B2 (ja) * | 1999-06-04 | 2010-07-14 | 長瀬産業株式会社 | 軸不斉を有する光学活性な４級アンモニウム塩、その製法およびα−アミノ酸誘導体の不斉合成への応用 |
| JP2004091342A (ja) * | 2002-08-29 | 2004-03-25 | Matsushita Electric Ind Co Ltd | 芳香族メチリデン化合物、それを製造するための化合物、それらの製造方法、及び芳香族メチリデン化合物を用いた有機電界発光素子 |
| ITMI20030311A1 (it) * | 2003-02-21 | 2004-08-22 | Chiesi Farma Spa | Acidi 2-fenil-2-dialchil-acetici per il trattamento della malattia di alzheimer. |
| US7524870B2 (en) * | 2004-12-03 | 2009-04-28 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators |
| JP5272345B2 (ja) * | 2006-08-28 | 2013-08-28 | 東ソー株式会社 | ヘテロアセン誘導体、テトラハロターフェニル誘導体及びそれらの製造方法 |
| CN102596879B (zh) * | 2009-08-04 | 2015-01-28 | 奇斯药制品公司 | 制备1-(2-卤代联苯-4-基)-环丙烷羧酸的衍生物的方法 |
-
2008
- 2008-06-11 EP EP08158022A patent/EP2133322A1/en not_active Withdrawn
-
2009
- 2009-05-08 KR KR1020107027903A patent/KR101257217B1/ko not_active Expired - Fee Related
- 2009-05-08 GE GEAP200911997A patent/GEP20135800B/en unknown
- 2009-05-08 DK DK09761360.8T patent/DK2285765T3/da active
- 2009-05-08 WO PCT/EP2009/003288 patent/WO2009149797A1/en not_active Ceased
- 2009-05-08 EP EP09761360A patent/EP2285765B1/en active Active
- 2009-05-08 JP JP2011512846A patent/JP5642067B2/ja not_active Expired - Fee Related
- 2009-05-08 NZ NZ589087A patent/NZ589087A/en not_active IP Right Cessation
- 2009-05-08 RU RU2010146299/04A patent/RU2502721C2/ru not_active IP Right Cessation
- 2009-05-08 AU AU2009256959A patent/AU2009256959B2/en not_active Ceased
- 2009-05-08 CA CA2723878A patent/CA2723878C/en active Active
- 2009-05-08 BR BRPI0909560A patent/BRPI0909560A2/pt not_active IP Right Cessation
- 2009-05-08 UA UAA201013287A patent/UA101835C2/uk unknown
- 2009-05-08 CN CN2009801196647A patent/CN102046576B/zh not_active Expired - Fee Related
- 2009-05-08 AT AT09761360T patent/ATE552230T1/de active
- 2009-05-08 HR HRP20120517AT patent/HRP20120517T1/hr unknown
- 2009-05-08 PT PT09761360T patent/PT2285765E/pt unknown
- 2009-05-08 ME MEP-2010-200A patent/ME01160B/me unknown
- 2009-05-08 ES ES09761360T patent/ES2384368T3/es active Active
- 2009-05-08 SI SI200930272T patent/SI2285765T1/sl unknown
- 2009-05-08 PL PL09761360T patent/PL2285765T3/pl unknown
- 2009-05-08 MX MX2010012285A patent/MX2010012285A/es active IP Right Grant
- 2009-05-08 MY MYPI2010005220A patent/MY150280A/en unknown
- 2009-05-15 US US12/466,660 patent/US8076505B2/en active Active
-
2010
- 2010-11-08 ZA ZA2010/07977A patent/ZA201007977B/en unknown
- 2010-11-09 IL IL209209A patent/IL209209A/en not_active IP Right Cessation
- 2010-11-11 MA MA33338A patent/MA32297B1/fr unknown
- 2010-11-16 CO CO10143043A patent/CO6331461A2/es active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004074232A1 (en) * | 2003-02-21 | 2004-09-02 | Chiesi Farmaceutici S.P.A. | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases |
| EA200700860A1 (ru) * | 2004-10-21 | 2007-10-26 | Целльцом Аг | (бифенил)карбоновые кислоты и их производные |
| WO2006133559A1 (en) * | 2005-06-14 | 2006-12-21 | Merck Frosst Canada Ltd. | Reversible inhibitors of monoamine oxidase a and b |
Non-Patent Citations (1)
| Title |
|---|
| PERETTO, I. ET. AL: "Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of beta-Amyloid Secretion" JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 18, 2005, pages 5705-5720. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2502721C2 (ru) | Способ получения производных 1-(2-галогенобифенил-4-ил)-циклопропанкарбоновой кислоты | |
| JP6001112B2 (ja) | １−（２−ハロビフェニル−４−イル）−シクロプロパンカルボン酸の誘導体の調製方法 | |
| HK1168588B (en) | Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid | |
| HK1152292B (en) | Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid | |
| JPH1180076A (ja) | ２，３，４−トリフルオロ−５−ヨ−ド安息香酸、そのエステル類及びその製造法 | |
| JP2009019004A (ja) | 光学活性アリールオキシカルボン酸誘導体の製造方法 | |
| JP2005015402A (ja) | 光学活性３，５−ジヒドロ−４Ｈ−ジナフト［２，１−ｃ：１’，２’−ｅ］アゼピンおよびそのシュウ酸塩の製造方法 | |
| JP2010024142A (ja) | （アリーロイル又はヘテロアリーロイル）メチルペンタフルオロスルファニルベンゼン化合物の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180509 |